AUTHOR INDEX

ABBOTT D. *see* HOWES L.G.
ABDELMAWLA A.H., LANGLEY R.W., SZABADI E. & BRADSHAW C.M. Bisoprolol attenuates noradrenaline- and phenylephrine-evoked venoconstriction in man, 61
ABOSEHMAH-ALBIDY A.Z.M., YORK P., WONG V., LOSOWSKY M.S. & CHRYSTYN H. Improved bioavailability and clinical response in patients with chronic liver disease following the administration of a spironolactone: β-cyclodextrin complex, 35
ADEBAYO R.A., SOFOWORA G.G., ONAYEMI O., UDOH S.J. & AJAYI A.A. Chloroquine-induced pruritus in malaria fever: contribution of malaria parasitaemia and the effects of prednisolone, niacin, and their combination, compared with antihistamine, 157
AFFRIME M.B. *see* GLUE P.
AFFRIME M.B. *see* VAN RIEMSDIJK M.M.
AJAYI A.A. *see* ADEBAYO R.A.
AKAR F., SÖNMEZ UYDEŞ-DOGAN B., TUFAN H., AŞLAMACI S., KÖKSOY C. & KANZIK I. The comparison of the responsiveness of human isolated internal mammary and gastroepiploic arteries to levcromakalim: an alternative approach to the management of graft spasm, 49
AKHLAGHI F., McLACHLAN A.J., KEOGH A.M. & BROWN K.F. Effect of simvastatin on cyclosporine unbound fraction and apparent blood clearance in heart transplant recipients, 537
AL BUNNI M. *see* PADRINI R.
ALBENGRES E. *see* SIMON N.
ALVAREZ REQUEJO A. *see* CARO-PATON, T.
ANDREJAK M. *see* MOORE N.
ARMSTRONG J. *see* MARSHALL P.W.
ARTHUR N. *see* McGETTIGAN P.
AŞLAMACI S. *see* AKAR F.

BABER N.S., TUCKER G.T. & WEBB D.J. The Clinical Section of the British Pharmacological Society: prospects for the future, 215
BACK D.J. *see* EAGLING V.A.
BAKKER A. *see* EGBERTS A.C.G.
BANFIELD C.R. *see* RICHENS A.
BANFIELD C. *see* GLUE P.
BARNETT D.A. *see* JESSA M.J.
BARR C.S. *see* MACFADYEN R.J.
BARRE J. *see* SIMON N.
BARRETT J.S. *see* CHEN S.
BARRY M.G. *see* EAGLING V.A.
BAUD F. *see* RENARD C.
BAUER K.G., BRUNEL P., NELL G., QUINN G. & KAIK G.A. Benazepril, an angiotensin converting enzyme inhibitor: drug interaction with salbutamol and bronchial response to histamine in normal subjects, 573
BEAU N. *see* RENARD C.
BECH J.N. *see* NIELSEN, C.B.
BECKER T. *see* GLEITER C.H.
BEGAUD B. *see* HARAMBURU F.
BEGAUD B. *see* MOORE N.
BELPAIRE F.M. *see* PAN L.P.
BENNETT, T. *see* COCKROFT J.R.
BENZIE I.F.F., TOMLINSON B., CRITCHLEY J.A.J.H., LAPENNA D. & CUCCURULLO F. Captopril has no significant scavenging antioxidant activity in human plasma *in vitro* or *in vivo*, 209
BERGGREN-PALME I. *see* HELLGREN U.
BERGQVIST Y. *see* HELLGREN U.
BERLAND Y. *see* SIMON N.
BERNUS I., DICKINSON, R.G., HOOPER, W.D. & EADIE, M.J. The mechanism of the carbamazepine-valproate interaction in humans, 21
BERRAZUETA J.R., BHAGAT K., VALLANCE P. & MACALLISTER R.J. Dose- and time-dependency of the dilator effects of the endothelin antagonist, BQ-123, in the human forearm, 569
BERTILSSON K. *see* EIERMANN B.
BERTILSSON L., TYBRING G., WIDEN J., CHANG M. & TOMSON T. Carbamazepine treatment induces the CYP3A4 catalysed sulphoxidation of omeprazole, but has no or less effect on hydroxylation via CYP2C19, 186
BEYSENS A.J.M.M. *see* DE HOON J.N.J.M.
BHAGAT K. *see* BERRAZUETA J.R.
BOIOCCHI M. *see* TOFFOLI G.
BOOIJ L.H.D.J. *see* VREE T.B.
BOULTON D.W., FAWCETT J.P. & FIDDES T.M. Transplacental distribution of salbutamol enantiomers at Caesarian section, 587
BOYD A.H. *see* VAN MIERT M.M.
BRADSHAW C.M. *see* ABDELMAWLA A.H.
BROCKS D.R., UPWARD J., DAVY M., HOWLAND K., COMPTON C., McHUGH C. & DENNIS M.J. Evening dosing is associated with higher plasma concentrations of pranlukast, a leukotriene receptor antagonist, in healthy male volunteers, 289
BROWN K.F. *see* AKHLAGHI F.
BRUNEL P. *see* BAUER K.G.
BRUNET P. *see* SIMON N.

CALVERT R. *see* WOLFF K.
CARLEBORG L. *see* SPIGSET O.
CARO-PATON, T., CARVAJAL A., MARTIN DE DIEGO I., MARTIN-ARIAS L.H., ALVAREZ REQUEJO A. & RODRIGUEZ PINILLA E. Is metronidazole teratogenic? A meta-analysis, 179
CARVAJAL A. *see* CARO-PATON, T.
CHAN J.C.N. *see* LEE P.K.F.
CHANG M. *see* BERTILSSON L.
CHANG S. *see* LEE P.K.F.
CHANNI KUMAR R. *see* YOSHIDA K.
CHAPUT DE SAINTONGE D.M., EVANS S.J.W., CRANE G.J. & KIRWAN J.R. Clinical trials and clinical practice: do doctors use the same criteria to judge outcome? 583
CHAUVET-MONGES A.-M. *see* SIMON N.
CHEN S., KUMAR S., CHOU W.-H., BARRETT J.S. & WEDLUND P.J. A genetic bias in clinical trials? Cytochrome P450–2D6 (CYP2D6) genotype in general *vs* selected healthy subject populations, 303
CHEN W.P. *see* FU L.W.
CHIRON C. *see* JACQZ-AIGRAIN E.
CHOU W.-H. *see* CHEN S.
CHRYSTYN H. *see* ABOSEHMAH-ALBIDY A.Z.M.
CHRYSTYN H. *see* SMITH L.
CHUNG S.J. *see* LEE Y.J.
COCCI A. *see* CONFORTI A.
COCKROFT J.R., NOON, J.P., GARDNER-MEDWIN J. & BENNETT, T. Haemodynamic effects of adrenomedullin in human resistance and capacitance vessels, 57
COHEN A.F. *see* DINGEMANSE J.
COHEN A.F. *see* VAN GERVEN J.M.A.
COHEN A.F. *see* VAN STEVENINCK A.L.
COLUCCI R. *see* GLUE P.
COMPTON C. *see* BROCKS D.R.
CONFORTI A., GUGLIEMO L., NALDI L., COCCI A., VENEGONI M. & LEONE R. Brodimoprim: adverse drug reactions from spontaneous reporting, 411
CONROY R.M. *see* McGETTIGAN P.
COOKE T. *see* WEN Y.
CRANE G.J. *see* CHAPUT DE SAINTONGE D.M.
CREVOISIER C. *see* DINGEMANSE J.
CRITCHLEY J.A.J.H. *see* BENZIE I.F.F.
CRITCHLEY J.A.J.H. *see* LEE P.K.F.
CUCCURULLO F. *see* BENZIE I.F.F.

D'ATHIS P. *see* SIMON N.
DACHMAN W.D. *see* VAJO Z.
DANHOF M. *see* VAN STEVENINCK A.L.
DAVIS J.D. *see* PRISKORN M.
DAVIS T.M.E. Antimalarial drugs and glucose metabolism, 1
DAVY M. *see* BROCKS D.R.
DE CICCO M. *see* TOFFOLI G.
DE HOON J.N.J.M., THIJSSEN H.H.W., BEYSENS A.J.M.M. & VAN BORTEL L.M.A.B. No effect of short-term omeprazole intake on acenocoumarol pharmacokinetics and pharmacodynamics, 399
DE KONING F.H.P. *see* EGBERTS A.C.G.
DE VRIENDT C. *see* PAN L.P.
DEMOLIS J.L., MARTEL C., FUNCK-BRENTANO C., SACHSE A., WEIMANN H.J. & JAILLON P. Effects

© 1997 Blackwell Science Ltd

of tedisamil, atenolol and their combination on heart and rate-dependent QT interval in healthy volunteers, 403
DENNIS M.J. *see* BROCKS D.R.
DICKINSON, R.G. *see* BERNUS I.
DILGER C. *see* WALTER K.
DINGEMANSE J. *see* VAN GERVEN J.M.A.
DINGEMANSE J., KLEINBLOESEM, C.H., ZURCHER, G., WOOD N.D. & CREVOISIER C. Pharmacodynamics of benserazide assessed by its effects on endogenous and exogenous levodopa pharmacokinetics, 41
DINGEMANSE J., VAN GERVEN J.M.A., SCHOEMAKER, R.C., RONCARI G., OBERYE J.J.L., VAN OOSTENBRUGGEN M.F., MASSARELLA J., SEGALA P., ZELL M. & COHEN A.F. Integrated pharmacokinetics and pharmacodynamics of Ro 48–6791, a new benzodiazepine, in comparison with midazolam during first administration to healthy male subjects, 477
DIXON R.M. *see* MARSHALL P.W.
DIXON R. *see* PECK R.W.
DUCHE C. *see* SIMON N.
DUSCI L.J. *see* WOJNAR-HORTON R.E.
DUSSOL B. *see* SIMON N.

EADIE, M.J. *see* BERNUS I.
EAGLING V.A., BACK D.J. & BARRY M.G. Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir, 190
EASTWOOD N.B. *see* VAN MIERT M.M.
ECKL K.M. *see* PUCHLER K.
EGBERTS A.C.G., MEYBOOM R.H.B., DE KONING F.H.P., BAKKER A. & LEUFKENS H.G.M. Non-puerperal lactation associated with antidepressant drug use, 277
EGERTON W.S. *see* ROBERTS M.S.
EICHLER H.G. *see* MATULLA B.
EIERMANN B., ENGEL G., JOHANSSON I., ZANGER U.M. & BERTILSSON K. The involvement of CYP1A2 and CYP3A4 in the metabolism of clozapine, 439
ENGEL G. *see* EIERMANN B.
ENTLICHER J. *see* MATULLA B.
ERNST E. Homeopathy: past, present and future, 435
EVANS S.J.W. *see* CHAPUT DE SAINTONGE D.M.

FANTIN D. *see* TOFFOLI G.
FAWCETT J.P. *see* BOULTON D.W.
FEELY J. *see* McGETTIGAN P.
FEELY J. *see* WEN Y.
FEELY M. *see* WOLFF K.
FENWICK M. *see* MACFADYEN R.J.
FERRARI M. *see* PADRINI R.
FERRO C.J., HAYNES W.G., JOHNSTON N.R., LOMAX C.C., NEWBY D.E. & WEBB D.J. The peptide endothelin receptor antagonist, TAK-044, produces sustained inhibition of endothelin^{-1}-mediated arteriolar vasoconstriction, 377
FIDDES T.M. *see* BOULTON D.W.
FINDL O. *see* MATULLA B.
FRITSCHE L. *see* PUCHLER K.
FRUSTACI S. *see* TOFFOLI G.
FU L.W., YANG L.Y., CHEN W.P. & LIN C.Y. Cyclosporin pharmacokinetics following administration of capsules and Neoral in paediatric patients with lupus nephritis, 125
FUDER H., STIEGLER S., WETZELSBERGER N., WIECKHORST N., LANGE R. & LUCKER P.W. Effect of buffering on pharmacokinetics of ketoprofen enantiomers in man, 527
FUNCK-BRENTANO C. *see* DEMOLIS J.L.

GARDNER-MEDWIN J. *see* COCKROFT J.R.
GIELEN M.J.M. *see* VREE T.B.
GIGANTE M. *see* TOFFOLI G.
GILLOTIN C.G. *see* PECK R.W.
GLEITER C.H., BECKER T. & WENZEL J. Erythropoietin production in healthy volunteers subjected to controlled hypobaric hypoxia: further evidence against a role for adenosine, 203
GLUE P. *see* VAN RIEMSDIJK M.M.
GLUE P., SULOWICZ W., COLUCCI R., BANFIELD C., PAI S., LIN C. & AFFRIME M.B. Single-dose pharmacokinetics of felbamate in patients with renal dysfunction, 91
GODDARD A.F. *see* JESSA M.J.
GOERDT P.J., HEIM-DUTHOY K.L., MACRES M. & SWAN S.K. Predictive performance of renal function estimate equations in renal allografts, 261
GOLDEN J. *see* McGETTIGAN P.
GORCHEIN A. Drug treatment in acute porphyria, 427
GRAHAME-SMITH D.G. 'Keep on taking the tablets': pharmacological adaptation during long-term drug therapy, 227
GRASELI U. *see* MATUALLA B.
GREENBLATT D.J. *see* SCHMIDER J.
GRENE-LEROUGE N. *see* RENARD C.
GROENEWOUD G. *see* MULLER F.O.
GROWCOTT J.W. *see* MARSHALL P.W.
GUGLIEMO L. *see* CONFORTI A.
GUILLONNEAU M. *see* JACQZ-AIGRAIN E.
GUSELLA M. *see* PADRINI R.

HACKETT L.P. *see* WOJNAR-HORTON R.E.
HALL C. *see* HENRY D.
HANRATTY C. *see* McAULEY D.
HARAMBURU F. *see* MOORE N.
HARAMBURU F., BEGAUD B. & MORIDE Y. Temporal trends in spontaneous reporting of unlabelled adverse drug reactions, 299
HAWARDEN D. *see* MULLER F.O.
HAY A.W.M. *see* WOLFF K.
HAYNES W.G. *see* FERRO C.J.
HE G.-W. & YANG C.-Q. Comparison of nitroprusside and nitroglycerin in inhibition of angiotensin II and other vasoconstrictor-mediated contraction in human coronary bypass conduits, 361
HE G.-W. & YANG C.-Q. Inhibition of vasoconstriction by potassium channel opener aprikalim in human conduit arteries used as bypass grafts, 353
HEIM-DUTHOY K.L. *see* GOERDT P.J.
HEIZMANN P. *see* VAN GERVEN J.M.A.
HELLGREN U., BERGGREN-PALME I., BERGQVIST Y. & JERLING M. Enantioselective pharmacokinetics of mefloquine during long-term intake of the prophylactic dose, 119
HENRY D. *see* HILL S.
HENRY D., J., WHYTE I., NANRA R. & HALL C. Consumption of non-anti-inflammatory drugs and the development of functional renal impairment in elderly subjects. Results of a case-control study, 85
HILL S., HENRY D., PERKARSKY B. & MITCHELL A. Economic evaluation of pharmaceuticals: what are reasonable standards for clinical evidence — the Australian experience, 421
HOOPER, W.D. *see* BERNUS I.
HOWES L.G., ABBOTT D. & STRAZNICKY N.E. Lipoproteins and cardiovascular reactivity, 319
HOWLAND K. *see* BROCKS D.R.
HUANG SONG-LIN *see* WANG JUN-SHENG
HUNDT H.K.L. *see* MULLER F.O.
HUNTER J.M. *see* VAN MIERT M.M.

ILLETT K.F. *see* WOJNAR-HORTON R.E.
ISELIUS L. *see* YUE Q.Y.
ISHIZAKI T. *see* ZHAO X.-J.
IVERSEN L. Principles of Neuropharmacology (Book review), 519

JACQZ-AIGRAIN E., GUILLONNEAU M., REY E., MACHER M.-A., MONTES C., CHIRON C. & LOIRAT C. Pharmacokinetics of the S(+) and R(-) enantiomers of vigabatrin during chronic dosing in a patient with renal failure, 183
JAILLON P. *see* DEMOLIS J.L.
JENSEN P. *see* VAN RIEMSDIJK M.M.
JERLING M. *see* HELLGREN U.
JERLING M., MERLE Y., MENTRE F. & MALLET A. Population pharmacokinetics of clozapine evaluated with the nonparametric maximum likelihood method, 447
JESSA M.J., GODDARD A.F., BARNETT D.A., SHAW P.N. & SPILLER R.C. The effect of omeprazole on the pharmacokinetics of metronidazole and hydroxymetronidazole in human plasma, saliva and gastric juice, 245
JICK H. *see* MEIER C.R.

© 1997 Blackwell Science Ltd *Br J Clin Pharmacol*, 44, 601–605

JOHANSSON I. *see* EIERMANN B.
JOHNSTON G.D. *see* McAULEY D.
JOHNSTON N.R. *see* FERRO C.J.
JONES, A.W., JONSSON K.A. & KECHAGIAS S. Effect of high-fat, high-protein, and high-carbohydrate meals on pharmacokinetics of a small dose of ethanol, 521
JONES T.E., MORRIS R.G. & MATHEW T.H. Diltiazem-cyclosporin pharmacokinetic interaction—dose–response relationship, 499
JONSSON K.A. *see* JONES, A.W.

KAIK G.A. *see* BAUER K.G.
KANZIK I. *see* AKAR F.
KARSOV D. *see* SCHMIDER J.
KECHAGIAS S. *see* JONES, A.W.
KEESMAAT P. *see* VAN GERVEN J.M.A.
KEOGH A.M. *see* AKHLAGHI F.
KERWIN R. Fundamentals of Psychopharmacology (Book review), 519
KHAN A.Z. *see* PRISKORN M.
KIRKWOOD L.C., NATION R.L. & SOMOGYI A.A. Characterization of the human cytochrome-P450 enzymes involved in the metabolism of dihydrocodeine, 549
KIRWAN J.R. *see* CHAPUT DE SAINTONGE D.M.
KLEINBLOESEM, C.H. *see* DINGEMANSE J.
KNASS D. *see* SMITH L.
KÖKSOY C. *see* AKAR F.
KOKWARO G.O. Bioavailability of artemether, 305
KOOYMAN H. *see* VAN GERVEN J.M.A.
KREFT-JAIS C. *see* MOORE N.
KRISTENSEN J.H. *see* WOJNAR-HORTON R.E.
KRUM H. β-adrenoceptor blockers in chronic heart failure — a review, 111
KUMAR S. *see* CHEN S.

LANGE R. *see* FUDER H.
LANGLEY R.W. *see* ABDELMAWLA A.H.
LAPENNA D. *see* BENZIE I.F.F.
LARSEN F. *see* PRISKORN M.
LAVRIJSSEN A.T.J. *see* PUCHLER K.
LAWSON D.H. Pharmacovigilance in the 1990s, 109
LAYTON G. *see* PECK R.W.
LEE P.K.F., LI R.K.L., CHAN J.C.N., CHANG S., LEE S.C., TOMLINSON B. & CRITCHLEY J.A.J.H. A prescription survey in a hospital hypertension outpatient clinic, 577
LEE S.C. *see* LEE P.K.F.
LEE Y.J., CHUNG S.J. & SHIM C.K. Decreased oral availability of cyclosporin A at second adminstration in humans, 343
LENNARD L., WELCH J.C. & LILLEYMAN J.S. Thiopurine drugs in the treatment of childhood leukaemia: the influence of inherited thiopurine methyltransferase activity on drug metabolism and cytotoxicity, 455
LEONE R. *see* CONFORTI A.
LEUFKENS H.G.M. *see* EGBERTS A.C.G.
LI R.K.L. *see* LEE P.K.F.
LILLEYMAN J.S. *see* LENNARD L.
LIN C.C. *see* VAN RIEMSDIJK M.M.
LIN C. *see* GLUE P.
LIN C.Y. *see* FU L.W.
LIP G.Y.H. *see* MAXWELL S.R.J.
LIPPERT T.H. *see SEEGER* H.
LIPWORTH B.J. *see* TAN K.S.
LIPWORTH B. *see* VOZEH S.
LOIRAT C. *see* JACQZ-AIGRAIN E.
LOMAX C.C. *see* FERRO C.J.
LOSOWSKY M.S. *see* ABOSEHMAH-ALBIDY A.Z.M.
LUCKER P.W. *see* FUDER H.
LYONS, D. *see* PRITCHARD G.

MACALLISTER R.J. *see* BERRAZUETA J.R.
MACDONALD T.M. *see* PRITCHARD G.
MACFADYEN R.J., BARR C.S., STURROCK N.D.C., FENWICK M. & STRUTHERS A.D. Further evidence that chronic perindopril treatment maintains neurohormonal supression but does not lower blood pressure in chronic cardiac failure, 69
MACHER M.-A. *see* JACQZ-AIGRAIN E.
MACRES M. *see* GOERDT P.J.
MAGNOLFI G. *see* PADRINI R.
MAGUIRE S. *see* McAULEY D.
MAIOLINO P. *see* PADRINI R.
MALLET A. *see* JERLING M.
MALLY J. Aminophylline and essential tremor, 412
MARAIS K. *see* MULLER F.O.
MARSHALL P.W., WILLIAMS A.J., DIXON R.M., GROWCOTT J.W., WARBURTON S., ARMSTRONG J. & MOORES J. A comparison of the effects of aspirin on bleeding time measured using the Simplate™ method and closure time measured using the PFA-100TM, in healthy volunteers, 151
MARTEL C. *see* DEMOLIS J.L.
MARTIN DE DIEGO I. *see* CARO-PATON, T.
MARTIN-ARIAS L.H. *see* CARO-PATON, T.
MASSARELLA J. *see* DINGEMANSE J.
MASSARELLA J. *see* VAN GERVEN J.M.A.
MATHEW T.H. *see* JONES T.E.
MATULLA B., STREIT G., PIEH S., FINDL O., ENTLICHER J., GRASELI U., EICHLER H.G., WOLZT M. & SCHMETTERER L. Effects of losartan on cerebral and ocular circulation in healthy subjects, 369
MAXWELL S.R.J. & LIP G.Y.H. Free radicals and antioxidants in cardiovascular disease, 307
McAULEY D., McGURK C., NUGENT A.G., HANRATTY C., MAGUIRE S. & JOHNSTON G.D. Forearm endothelium-dependent vascular responses and the potassium-ATP channel, 292
McDONALD M. *see* VAJO Z.
McFARLANE L.C. *see* TAN K.S.
McGETTIGAN P., GOLDEN J., CONROY R.M., ARTHUR N. & FEELY J. Reporting of adverse drug reactions by hospital doctors and the response to intervention, 98
McGOWAN L. *see* SMITH L.
McGURK C. *see* McAULEY D.
McHUGH C. *see* BROCKS D.R.
MCLACHLAN A.J. *see* AKHLAGHI F.
MEIER C.R. & JICK H. Omeprazole, other antiulcer drugs and newly diagnosed gout, 175
MENTRE F. *see* JERLING M.
MERLE Y. *see* JERLING M.
MEYBOOM R.H.B. *see* EGBERTS A.C.G.
MICHAEL A. *see* OSAMAH H.
MIDDLE M.V. *see* MULLER F.O.
MIRA R. *see* OSAMAH H.
MITCHELL A. *see* HILL S.
MONTES C. *see* JACQZ-AIGRAIN E.
MOORE N., KREFT-JAIS C., HARAMBURU F., NOBLET C., ANDREJAK M., OLLAGNEIR M. & BEGAUD B. Reports of hypoglycaemia associated with the use of ACE inhibitors and other drugs: a case/non-case study in the French pharmacovigilance system database, 513
MOORES J. *see* MARSHALL P.W.
MORIDE Y. *see* HARAMBURU F.
MORRIS R.G. *see* JONES T.E.
MOSS-BARCLAY C. *see* SMITH L.
MUECK A.O. *see SEEGER* H.
MULLER F.O., MIDDLE M.V., SCHALL R., TERBLANCHE J., HUNDT H.K.L. & GROENEWOUD G. An evaluation of the interaction of meloxicam with frusemide in patients with compressed chronic cardiac failure, 393
MULLER F.O., TERBLANCE J., SCHALL R., VAN ZYL SMIT R., TUCKER T., MARAIS K., GROENEWOUD G., PORCHET H.C., WEINER M. & HAWARDEN D. Pharmacokinetics of triptorelin after intravenous bolus administration in healthy males and in males with renal or hepatic insufficiency, 335

NALDI, L. *see* CONFORTI A.
NANRA R. *see* HENRY D.
NATION R.L. *see* KIRKWOOD L.C.
NELL G. *see* BAUER K.G.
NEUMEYER H.-H. *see* PUCHLER K.
NEWBY D.E. *see* FERRO C.J.
NICOLOSI G.L. *see* TOFFOLI G.
NIELSEN, C.B., BECH J.N. & PEDERSEN E.B. Effects of prostacyclin on renal haemodynamics, renal tubular function and vasoactive hormones in healthy humans. A placebo-controlled dose-response study, 471
NOBLET C. *see* MOORE N.

NOMEIR A. *see* RICHENS A.
NOON, J.P. *see* COCKROFT J.R.
NORSTROM A. *see* SPIGSET O.
NUGENT A.G. *see* McAULEY D.
NUSSEY S.S. *see* SHOTLIFF K.

OBERYE J.J.L. *see* DINGEMANSE J.
OHMAN R. *see* SPIGSET O.
OLLAGNEIR M. *see* MOORE N.
ONAYEMI O. *see* ADEBAYO R.A.
ORLANDO R. & PALATINI P. The effect of age on plasma MEGX concentrations, 206
ORME M. Education in Clincial Pharmacology and Therapeutics in a changing world, 107
OSAKI T. *see* UETA E.
OSAMAH H., MIRA R., SORINA S., SHLOMO K. & MICHAEL A. Reduced platelet aggregation after fluvastatin therapy is associated with altered platelet lipid composition and drug binding to the platelets, 77

PADRINI R., GUSELLA M., AL BUNNI M., PIOVAN D., ZORDAN R., MAGNOLFI G., MAIOLINO P. & FERRARI M. Tolerance to the repolarization effects of *rac*-sotalol during long-term treatment, 463
PAGE J. *see* HENRY D.
PAI S. *see* GLUE P.
PALATINI P. *see* ORLANDO R.
PAN L.P., WIJNANT P., DE VRIENDT C., ROSS*SEE*L M.T. & BELPAIRE F.M. Characterization of the cytochrome P450 isoenzymes involved in the *in vitro* *N*-dealkylation of haloperidol, 557
PARKER C.J. R *see* VAN MIERT M.M.
PECK R.W., SEABER E.J., DIXON R., GILLOTIN C.G., WEATHERLEY B.C., LAYTON G. & POSNER J. The interaction between propranolol and the novel antimigraine agent zolmitriptan (311C90), 595
PEDERSEN E.B. *see* NIELSEN, C.B.
PEPPLINKHUIZEN L. *see* VAN RIEMSDIJK M.M.
PERKARSKY B. *see* HILL S.
PETRIE J.C. *see* PRITCHARD G.
PIEH S. *see* MATUALLA B.
PIETERS M.S.M. *see* VAN STEVENINCK
PIOVAN D. *see* PADRINI R.
PORCHET H.C. *see* MULLER F.O.
PORCHET H.C. *see* MULLER F.O.
POSNER J. *see* PECK R.W.
PRISKORN M., SIDHU J.S., LARSEN F., DAVIS J.D., KHAN A.Z. & ROLAN P.E. Investigation of multiple dose citalopram on the pharmacokinetics and pharmacodynamics of racemic warfarin, 199
PRITCHARD G., LYONS, D., WEBSTER J., PETRIE J.C. & MacDONALD T.M. Do trandolapril and indomethacin influence renal function and renal function reserve in hypertensive patients, 145
PUCHLER K., ECKL K.M., FRITSCHE L., RENNEISEN K., NEUMEYER H.-H., SIERAKOWSKI B., LAVRIJSSEN A.T.J., THOMSEN T. & ROOTS I. Pharmacokinetics of temocapril and temocaprilat after 14 once daily oral doses of temocapril in hypertensive patients with varying degrees of renal impairment, 531

QUINN G. *see* BAUER K.G.

RAISTRICK D. *see* WOLFF K.
REID J.L. Clinical Pharmacology and Therapeutics — past, present and future, 101
REID J.L., RUBIN P.C., WHITING B. & WALLER D. Lecture Notes on Clinical Pharmacology — 5th edition (Book review), 306
RENARD C., GRENE-LEROUGE N., BEAU N., BAUD F. & SCHERRMANN J.M. Pharmacokinetics of digoxin-specific Fab: effects of decreased renal function and age, 135
RENNEISEN K. *see* PUCHLER K.
REY E. *see* JACQZ-AIGRAIN E.
RICHENS A., BANFIELD C.R., SALFI M. & NOMEIR A. Single and multiple dose pharmacokinetics of felbamate in the elderly, 129
RIVORY L.P. *see* ROBERTS M.S.
ROBERTS M.S., WU Z.Y., RIVORY L.P., SMITHERS B.M., EGERTON W.S. & WEISS M. Relative dispersion of intravascular transit times during human isolated limb perfusion for recurrent melanoma, 347
ROBIEUX I. *see* TOFFOLI G.
RODRIGUEZ PINILLA E. *see* CARO-PATON, T.
ROLAN P.E. *see* PRISKORN M.
ROLAN P. The contribution of clinical pharmacology surrogates and models to drug development — a critical appraisal, 219
RONCARI G. *see* DINGEMANSE J.
RONCARI G. *see* VAN GERVEN J.M.A.
ROOTS I. *see* PUCHLER K.
ROSSEEL M.T. *see* PAN L.P.
ROSTAMI-HODJEGAN L. *see* WOLFF K.
ROUMENOV D. *see* SIMON N.
RUBIN P.C. *see* REID J.L.

SACHSE A. *see* DEMOLIS J.L.
SALFI M. *see* RICHENS A.
SAWE J. *see* YUE Q.Y.
SCHALL R. *see* MULLER F.O.
SCHERRMANN J.M. *see* RENARD C.
SCHMETTERER L. *see* MATUALLA B.
SCHMIDER J., GREENBLATT D.J., VAN MOLTKE L.L., KARSOV D. & SHADER R.I. Inhibition of CYP2C9 by selective serotonin reuptake inhibitors *in vitro*: studies of phenytoin *p*-hydroxylation, 495
SCHOEMAKER R.C. *see* VAN GERVEN J.M.A.
SCHOEMAKER R.C. *see* VAN STEVENINCK A.L.
SCHOEMAKER, R.C. *see* DINGEMANSE J.
SEABER E.J. *see* PECK R.W.
SEEGER H., MUECK A.O. & LIPPERT T.H. Effect of melatonin and metabolites on copper-mediated oxidation of low density lipoprotein, 283
SEGALA P. *see* DINGEMANSE J.
SHADER R.I. *see* SCHMIDER J.
SHAW P.N. *see* JESSA M.J.
SHIM C.K. *see* LEE Y.J.
SHIRES, S. *see* WOLFF K.
SHLOMO K. *see* OSAMAH H.
SHOTLIFF K. & NUSSEY S.S. Medroxyprogesterone acetate induced Cushing's syndrome, 304
SIDHU J.S. *see* PRISKORN M.
SIERAKOWSKI B. *see* PUCHLER K.
SIMON M.A.M. *see* VREE T.B.
SIMON N., BRUNET P., ROUMENOV D., DUSSOL B., BARRE J., DUCHE C., ALBENGRES E., D'ATHIS P., CHAUVET-MONGES A.-M., BERLAND Y. & TILLEMENT J.-P. Trimetazidine does not modify blood levels and immunosuppressant effects of cyclosporine A in renal allograft recipients, 591
SMITH B. *see* YOSHIDA K.
SMITH L., McGOWAN L., MOSS-BARCLAY C., WHEATER J., KNASS D. & CHRYSTYN H. An investigation of hospital generated pharmaceutical care when patients are discharged home from hospital, 163
SMITHERS B.M. *see* ROBERTS M.S.
SOFOWORA G.G. *see* ADEBAYO R.A.
SOMOGYI A.A. *see* KIRKWOOD L.C.
SONMEZ UYDES-DOGAN B. *see* AKAR F.
SORINA S. *see* OSAMAH H.
SPIGSET O., CARLEBORG L., OHMAN R. & NORSTROM A. Excretion of citalopram in breast milk, 295
SPILLER R.C. *see* JESSA M.J.
SRAZNICKY N.E. *see* HOWES L.G.
SRIVATHSAN K. *see* VAJO Z.
STIEGLER S. *see* FUDER H.
STRAZNICKY N.E. *see* HOWES L.G.
STREIT G. *see* MATUALLA B.
STRICKER B.H. Ch. *see* VAN RIEMSDIJK M.M.
STRUTHERS A.D. *see* MACFADYEN R.J.
STURROCK N.D.C. *see* MACFADYEN R.J.
SULOWICZ W. *see* GLUE P.
SWAN S.K. *see* GOERDT P.J.
SZABADI E. *see* ABDELMAWLA A.H.

TAKAHASHI B. *see* VAJO Z.
TAN K.S., McFARLANE L.C. & LIPWORTH B.J. Effects of oral and inhaled corticosteroid on lymphocyte β_2-adrenoceptor function in asthmatic patients, 565

© 1997 Blackwell Science Ltd

TERBLANCE J. *see* MULLER F.O.
THIJSSEN H.H.W. *see* DE HOON J.N.J.M.
THOMSEN T. *see* PUCHLER K.
TILLEMENT J.-P. *see* SIMON N.
TOFFOLI G., ROBIEUX I., FANTIN D., GIGANTE M., FRUSTACI S., NICOLOSI G.L., DE CICCO M. & BOIOCCHI M. Non-linear pharmacokinetics of high-dose intravenous verapamil, 255
TOMLINSON B. *see* BENZIE I.F.F.
TOMLINSON B. *see* LEE P.K.F.
TOMSON T. *see* BERTILSSON L.
TUCKER G.T. *see* BABER N.S.
TUCKER G.T. *see* WOLFF K.
TUCKER T. *see* MULLER F.O.
TUFAN H. *see* AKAR F.
TYBRING G. *see* BERTILSSON L.

UDOH S.J. *see* ADEBAYO R.A.
UETA E., YONEDA K., YAMAMOTO T. & OSAKI T. Influence of SNN-6010, an elemental diet, on the generation of cytokines, NO, and chemiluminescence from leukocytes and umbilical vein endothelial cells in man, 385
UPWARD J. *see* BROCKS D.R.
URQUHART J. Can drug delivery systems deliver value in the new pharmaceutical workplace? 413

VAJO Z., McDONALD M., TAKAHASHI B., ZAFAR H., SRIVATHSAN K. & DACHMAN W.D. Bradykinin-induced venodilation is not different in blacks, 285
VALLANCE P. *see* BERRAZUETA J.R.
VAN BORTEL L.M.A.B. *see* DE HOON J.N.J.M.
VAN DER KLAUW M.M. *see* VAN RIEMSDIJK M.M.
VAN GERVEN J.M.A. *see* DINGEMANSE J.
VAN GERVEN J.M.A. *see* VAN STEVENINCK
VAN GERVEN J.M.A., RONCARI G., SCHOEMAKER R.C., MASSARELLA J., KEESMAAT P., KOOYMAN H., HEIZMANN P., ZELL M., COHEN A.F. & DINGEMANSE J. Integrated pharmacokinetics and pharmacodynamics of Ro 48–8684 a new benzodiazepine, in comparison with midazolam, 487
VAN MIERT M.M., EASTWOOD N.B., BOYD A.H., PARKER C.J. R & HUNTER J.M. The pharmacokinetics and pharmacodynamics of rocuronium in patients with hepatic cirrhosis, 139
VAN MOLTKE L.L. *see* SCHMIDER J.
VAN OOSTENBRUGGEN M.F. *see* DINGEMANSE J.
VAN RIEMSDIJK M.M., VAN DER KLAUW M.M., PEPPLINKHUIZEN L., STRICKER B.H.Ch., LIN C.C., JENSEN P., AFFRIME M.B. & GLUE P. Spontaneous reports of psychiatric adverse effects to mefloquine in the Netherlands, 105
VAN STEVENINCK A.L., WALLNOFER A.E., SCHOEMAKER R.C., PIETERS M.S.M., DANHOF M., VAN GERVEN J.M.A. & COHEN A.F. A study of the effects of long-term use on individual sensitivity to temazepam and lorazepam in a clinical population, 267
VAN ZYL SMIT R. *see* MULLER F.O.
VENEGONI M. *see* CONFORTI A.
VOZEH S. & LIPWORTH B. Pharmacokinetics of inhaled drugs, 213
VREE T.B., SIMON M.A.M., GIELEN M.J.M. & BOOIJ L.H.D. J. Regional metabolism of articaine in 10 patients undergoing intravenous regional anaesthesia during day case surgery, 29

WALLER D. *see* REID J.L.
WALLEY T. & WEBB D.J. Developing a core curriculum in clinical pharmacology and therapeutics: a Delphi study, 167
WALLEY T. & WEBB D.J. Core content of a course in Clinical Pharmacology, 171
WALLNOFER A.E. *see* VAN STEVENINCK A.L.
WALTER K. & DILGER C. Ibuprofen in human milk, 211
WANG JUN-SHENG, WANG WEI, XIE HON-GUANG, HUANG SONG-LIN & ZHOU HONG-HAO Effect of troleandomycin on the pharmacokinetics of imipramine in Chinese: the role of CYP3A, 195
WANG WEI *see* WANG JUN-SHENG
WARBURTON S. *see* MARSHALL P.W.
WEATHERLEY B.C. *see* PECK R.W.
WEBB D.J. Endothelin: from molecule to man, 9
WEBB D.J. *see* BABER N.S.
WEBB D.J. *see* FERRO C.J.
WEBB D.J. *see* WALLEY T.
WEBSTER J. *see* PRITCHARD G.
WEDLUND P.J. *see* CHEN S.
WEIMANN H.J. *see* DEMOLIS J.L.
WEINER M. *see* MULLER F.O.
WEISS M. *see* ROBERTS M.S.
WELCH J.C. *see* LENNARD L.
WEN Y., COOKE T. & FEELY J. The effect of pharamcological supplementation with vitamin C on low-density lipoprotein oxidation, 94
WENZEL J. *see* GLEITER C.H.
WETZELSBERGER N. *see* FUDER H.
WHEATER J. *see* SMITH L.
WHITING B. *see* REID J.L.
WHYTE I. *see* HENRY D.
WIDEN J. *see* BERTILSSON L.
WIECKHORST N. *see* FUDER H.
WIJNANT P. *see* PAN L.P.
WILLIAMS A.J. *see* MARSHALL P.W.
WOJNAR-HORTON R.E., KRISTENSEN J.H., YAPP P., ILLETT K.F., DUSCI L.J. & HACKETT L.P. Methadone distribution and excretion into breast milk of clients in a methadone mainstream programme, 543
WOLFF K., ROSTAMI-HODJEGAN L., SHIRES, S., HAY A.W.M., FEELY M., CALVERT R., RAISTRICK, D. & TUCKER G.T. The pharmacokinetics of methadone in healthy subjects and opiate users, 325
WOLZT M. *see* MATUALLA B.
WONG V. *see* ABOSEHMAH-ALBIDY A.Z.M.
WOOD N.D. *see* DINGEMANSE J.
WU Z.Y. *see* ROBERTS M.S.

XIE HON-GUANG *see* WANG JUN-SHENG

YAMAMOTO T. *see* UETA E.
YANG C.-Q. *see* HE G.-W.
YANG L.Y. *see* FU L.W.
YAPP P. *see* WOJNAR-HORTON R.E.
YONEDA K. *see* UETA E.
YORK P. *see* ABOSEHMAH-ALBIDY A.Z.M.
YOSHIDA K., SMITH B. & CHANNI KUMAR R. Fluvoxamine in breast-milk and infant development, 210
YUE Q.Y., ISELIUS L. & SAWE J. Indices and graphical approaches for the detection of interindividual and interethnic variations in codeine metabolism, 239

ZAFAR H. *see* VAJO Z.
ZANGER U.M. *see* EIERMANN B.
ZELL M. *see* DINGEMANSE J.
ZELL M. *see* VAN GERVEN J.M.A.
ZHAO X.-J. & ISHIZAKI T. Metabolic interactions of selected antimalarial and non-antimalarial drugs with the major pathway (3-hydroxylation) of quinine in human liver microsomes, 505
ZHOU HONG-HAO *see* WANG JUN-SHENG
ZORDAN R. *see* PADRINI R.
ZURCHER, G. *see* DINGEMANSE J.

SUBJECT INDEX

This index was compiled from the keywords

ACE inhibition, 69
ACE inhibitors, 513, 531
Acenocoumarol, 399
Acute porphyria, 427
  Admixture analysis, 239
Adrenergic, 111
Adrenomedullin, 57
Adverse drug reaction reporting systems, 277
Adverse drug reactions, 98, 105, 411
Age, 129, 135, 267
Ageing, 206
Aldosterone, 471
Aminophylline, 412
Angiotensin II, 361, 369, 471
Angiotensin converting enzyme, 573
Angiotensin converting enzyme inhibitors, 577
Anti-epileptic drug, 129
Antidepressant drugs, 277
Antihistamines, 157
Antihypertensive drugs, 577
Antimalarial drugs, 1, 505
Antioxidant activity, 209
Antioxidant, 94, 309
Aprikalim, 353
Artemether, 305
Arteries, 57
Articaine, 29
Articainic acid, 29
Aspirin, 151
Asthma, 289, 565
Atenolol, 403
Atherosclerosis, 94
Atrial natriuretic peptide, 471
Australian guidelines, 421

β-adrenoceptor blocking agents, 111, 577
β_1-adrenoceptor antagonist, 61
β-cyclodextrin, 35
BQ-123, 569
Benazepril, 573
Benserazide, 41
Benzodiazepines, 267, 477, 487
Bioavailability, 35, 305, 521
Bioequivalence, 343
Bisoprolol, 61
Blacks, 285
Bleeding time, 151
Blood ethanol, 521
Blood flow, 57
Blood pressure, 471
Blood pressure response, 69
Book review, 306, 519
Bradycardic agents, 403
Bradykinin, 285
Breast milk, 210, 211, 295
British Pharmacological Society, 215
Brodimoprim, 411

CGRP, 57
CYP1A2, 439
CYP2C19, 186
CYP2D6, 549
CYP2C9 495
CYP3A, 195, 549
CYP3A4, 186, 439, 505
CYP450 isozymes, 190
Caesarean section, 587
Calcium channel blocking agents, 577
Captopril, 209
Carbamazepine, 186
Carbamazepine-epoxide, 21
Carbamazepine-trans-diol, 21
Carbamazepine-valproate interaction, 21
Career prospects, 101
Case–non-case methodology, 513
Caucasian, 239
Cerebral blood flow, 369
Chinese, 239
Chloroquine, 157
Cholesterol, 319
Chronic cardiac failure, 69
Chronobiology, 289
Chronopharmacokinetics, 289
Cimitidine, 175
Citalopram, 199, 295
Clearance, 537
Clinical importance, 583
Clinical judgement, 583
Clinical pharmacology and therapeutics, 167, 171
Clinical pharmacology, 101
Clinical section, 215
Clinical trials, 583
Clozapine, 439, 447
Codeine metabolism, 239
Concentration-effect relationships, 267
Congestive heart failure, 111
Core curriculum, 167, 171
Coronary artery disease, 307
Cost-effective analysis, 421
CsA, 343
Cyclosporine A, 125, 499, 537
Cytochrome P450, 495
Cytochrome P450 isoenzymes, 557
Cytochrome P450–2D6, 303
Cytokines, 385

Debrisoquine, 239
Decapeptyl R, 335
Decarboxylase, 41
Delphi study, 167
Desipramine, 195
Desmethylsertraline, 495
Differential profile of effect, 69
Digitalis intoxication, 135
Dihydrocodeine, 549
Dipyridamole, 203
Discharge medication, 163
Diuretics, 577
Domiciliary visit, 163
Doppler sonography 369
Dorsal hand vein, 61
Drug absorption, 289
Drug development, 219
Drug interaction, 537
Drug-drug interaction, 199

Education, 107
Elderly, 85
Electrolyte handling, 69
Enantiomers, 119, 183, 587
Endothelin, 9, 569
Endothelin antagonist, 569
Endothelium-dependent vasodilation, 292
Epoxide hydrolase, 21
Erythropoietin, 203
Ethnic groups, 239

Felbamate, 91, 125
First-pass metabolism, 521
Fluticasone, 565
Fluvastatin, 77
Fluvoxamine, 210
Food, 521
Forearm blood flow, 292
Fraction unbound, 537
Framing effects, 583
Free radical, 94

Gastric juice, 245
Gastric transfer, 245
Gastroepiploic artery, 49
Genotype, 303
Glipizide, 292
Glomerular filtration rate, 261
Glucose, 1
Glucuronidation, 21
GnRH 335
Gout, 175
Graphical methods, 239

HDL 319
Haloperidol, 551
Healthy subjects, 303
Healthy volunteers, 203
Heart transplant, 537
Helicobacter pylori, 245
Hepatic cirrhosis, 139
Histamine challenge, 573
Homeopathy, 435
Hospital doctors, 98
Human liver microsomes, 549, 551
Human milk, 543
Human volunteer study, 245
3-hydroxylation, 505
Hydroxymetronidazole, 245
Hypercholesterolaemia, 77
Hypobaric hypoxia, 203
Hypoglycaemia, 1

Ibuprofen, 211
Imipramine, 195
In vitro metabolism, 551
Indomethacin renal failure, 145
Induction, 186
Infant exposure, 543
Inhaled drugs, 212
Inhibition, 190
Insulin, 1
Interaction, 573, 595
Interleukin-2, 591
Internal mammary artery, 49

© 1997 Blackwell Science Ltd

Intervention, 98
Iohexol, 261
Isotopic renal function studies, 69

KATP 353
Ketoprofen enantiomers, 527

LDL 319
LDL cholesterol, 537
LDL-oxidation, 283
Lactation, 295
Leukotrienes, 289
Levcromakalim, 49
Levodopa, 41
Lilly Prize Lecture, 227
Lipid peroxidation, 94
Lipoproteins, 537
Liver blood flow, 521
Liver disease, 35
Lovastatin, 77
Lupus nephritis, 125
Lymphycyte β_2-adrenoceptors, 565

Macronutrients, 521
Magnesium hydroxide/citrate buffer, 527
Malaria parasite density, 157
Malformations, 179
Medical undergraduate education, 167, 171
Medroxyprogesterone, 304
Mefloquine, 105, 119
Melatonin, 283
6-mercaptopurine, 455
Meta-analysis, 179
Metabolic ratio, 239
Metabolism, 549
Metabolites, 283
Methadone, 543
Metronidazole, 179, 245
Migraine, 595
Milk : plasma ratio, 543
Models, 219
Monoethylglycinexylidine (MEXG), 206

Neoral, 125
Neurohormones, 69
Neuromuscular block, 139
Non-linear pharmacokinetics, 255
Non-puerperal lactation, 277
Non-steroidal anti-inflammatory drugs, 85, 527
Noradrenaline, 61

Omeprazole, 175, 186, 245

PAH/inulin, 145
PFA-100, 151
Parkinson's disease, 41
Perindopril, 69
Pharmacodynamics, 41, 199
Pharmacokinetics 29, 41, 91, 111, 125, 129, 135, 199, 245
Pharmacological adaptation, 227
Pharmacovigilance, 109
Phenylephrine, 61
Plasma renin activity, 203
Plasma, 245
Platelet aggregation, 77
Polymorphism, 239
Population pharmacokinetics, 119, 537
Potassium-ATP channel, 292
Pravastatin, 77
Prednisolone, 565
Prescription survey, 577
Propranolol, 595
Protease inhibitors, 190
Pruritus, 157
Psychomotor effects, 267

QT interval 403, 463

(R)- and (S)-warfarin, 199
Ranitidine, 175
Regional metabolism, 29
Renal allograft, 261
Renal dysfunction, 91
Renal failure, 135, 183, 531
Renal functional reserve, 145
Renal impairment, 85
Ro 48–6791, 477
Ro 48–8684. 487
Rocuronium, 139

SNN-6010 385
Salbutamol, 573, 587
Saliva, 245
Seamless pharmaceutical care, 163
Selective serotonin reuptake inhibitors, 295
Serotonin, 277
Simplate, 151
Simvastatin, 537
SmithKline Beecham Prize Lecture, 9
Soluble interleukin-2 receptors, 591
Spasm, 49
Specific Fab, 135
Spironolactone, 35
Spontaneous reporting, 105, 299, 411
Surrogates, 219
Sympathetic, 111

Temocapril, 531
Temocaprilat, 531
Theophylline, 203
Therapeutics, 101
Tocolysis, 587
Tolerance, 227, 267
Trandolapril, 145
Transplacental distribution, 587
Tremor, 412
Trimetazidine, 591
Troleandomycin, 195

Unlabelled effects, 299

VLDL 319
Validation, 219
Vasodilation, 285
Vein EDRF, 285
Veins, 57
Verapamil, 255
Vigabatrin, 183
Vitamins C and E, 94
Volunteers, 151

Warfarin, 199

Zolmitriptan, 595